Transitioning From Thrombopoietin Agonists to the Novel SYK Inhibitor Fostamatinib: A Multicenter, Real-World Case Series
Journal of the Advanced Practitioner in Oncology · 01.07.2021 · 12 (5)
DOI: 10.6004/jadpro.2021.12.5.6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Advanced Practitioner in Oncology, online erschienen am 01.07.2021. Verfasst von David M Hughes und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Boston Medical Center, Boston, Massachusetts. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Fostamatinib is an oral spleen tyrosine kinase (SYK) inhibitor used for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Clinical and operational barriers may exist that warrant bridging or switching from thrombopoietin receptor agonists (TPO-RAs), such as volatility or unpredictability of platelets, adverse events, and quality of life or patient preference. While fostamatinib demonstrated durable platelet responses, the safety and efficacy in combination, bridging, and/or switching with TPO-RAs is not well documented. The objective of this article is to provide guidance from real-world case studies for a safe and effective strategy for the transitioning of patients from TPO-RAs to fostamatinib, with some degree of overlap between the two agents. Currently, the evidence does not exist to guide the safe and effective use of combination therapy or transition between therapies in ITP. This case series highlights the importance to further understand the complexities of managing this disease, as well as successfully combining, bridging, and/or switching patients over to fostamatinib without the need for rescue therapy or increase in adverse events. The need for real-world evidence that guides providers on the safety and efficacy of short- and long-term combination therapy of fostamatinib and TPO-RAs is crucial. The rationale for combination therapy is to target different pathways, platelet destruction, and production without added toxicities. Additionally, gradual tapering off of TPO-RAs may provide a more favorable clinical outcome when switching to fostamatinib. The need for additional data is necessary to provide clinicians with guidance when managing patients with ITP.
Autor:innen und Institutionen
- Department of Pharmacy, Boston Medical Center, Boston, Massachusetts.
- OptumCare Cancer Clinic, Las Vegas, Nevada.
- Avera Medical Group Oncology & Hematology, Aberdeen, South Dakota.
- Mount Sinai Health System, New York, New York.
- Department of Medicine, Boston University, Boston, Massachusetts.
Zitieren
APA
Hughes, D. M., Toste, C., Nelson, C., Escalon, J., Blevins, F., & Shah, B. (2021). Transitioning From Thrombopoietin Agonists to the Novel SYK Inhibitor Fostamatinib: A Multicenter, Real-World Case Series. Journal of the Advanced Practitioner in Oncology, 12(5). https://doi.org/10.6004/jadpro.2021.12.5.6
Vancouver
Hughes DM, Toste C, Nelson C, Escalon J, Blevins F, Shah B. Transitioning From Thrombopoietin Agonists to the Novel SYK Inhibitor Fostamatinib: A Multicenter, Real-World Case Series. Journal of the Advanced Practitioner in Oncology. 2021;12(5). doi:10.6004/jadpro.2021.12.5.6
BibTeX
@article{Hughes2021,
author = {Hughes, David M and Toste, Charina and Nelson, Christopher and Escalon, Juliet and Blevins, Frances and Shah, Bhavesh},
title = {Transitioning From Thrombopoietin Agonists to the Novel SYK Inhibitor Fostamatinib: A Multicenter, Real-World Case Series},
journal = {Journal of the Advanced Practitioner in Oncology},
year = {2021},
volume = {12},
number = {5},
doi = {10.6004/jadpro.2021.12.5.6}
}
EUVIMED